Cerenis Therapeutics Holding Stock Euronext Paris
Stocks
FR0012616852
Biotechnology & Medical Research
| Market Cap | 68.47M 78.28M 63.15M 58.33M 111M 7.47B 113M 755M 296M 3.68B 294M 288M 12.64B | P/E 2026 * |
-4.17x | P/E 2027 * | -6.55x |
|---|---|---|---|---|---|
| Enterprise Value | 74.27M 84.91M 68.5M 63.27M 120M 8.1B 122M 818M 321M 3.99B 319M 312M 13.71B | EV / Sales 2026 * |
15.9x | EV / Sales 2027 * | 5.26x |
| Free-Float |
82.07% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +1.31% |
| Manager | Title | Age | Since |
|---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 49 | 2019-09-05 |
| Director of Finance/CFO | - | - | |
| Chief Operating Officer | - | 2005-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Cyrille Tupin
BRD | Director/Board Member | 49 | 2019-09-05 |
Olivier Martinez
BRD | Director/Board Member | 52 | 2010-07-19 |
Christian Chavy
BRD | Director/Board Member | 76 | 2015-02-05 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.31% | +12.09% | - | - | 78.27M | |
| -4.14% | -8.06% | +57.35% | +117.24% | 56.98B | |
| +1.84% | +1.65% | +76.90% | +95.68% | 53.58B | |
| -3.66% | +2.00% | +17.70% | +457.70% | 25.63B | |
| -1.40% | -2.52% | -19.62% | -14.77% | 23.51B | |
| +2.43% | +5.86% | +46.56% | +0.42% | 19.43B | |
| -3.19% | 0.00% | +33.99% | -26.87% | 18.12B | |
| -6.84% | +2.18% | +203.03% | +348.11% | 16.46B | |
| +8.74% | +10.46% | +47.66% | - | 14.13B | |
| -0.53% | +1.97% | +25.36% | +196.93% | 14.35B | |
| Average | -0.59% | +1.16% | +54.33% | +146.81% | 26.91B | |
| Weighted average by Cap. | -1.15% | +0.29% | +54.83% | +137.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.66M 5.33M 4.3M 3.97M 7.53M 508M 7.66M 51.35M 20.17M 250M 20M 19.57M 860M | 14.72M 16.83M 13.57M 12.54M 23.79M 1.6B 24.19M 162M 63.69M 791M 63.17M 61.8M 2.72B |
| Net income | -19.83M -22.67M -18.29M -16.89M -32.05M -2.16B -32.59M -219M -85.81M -1.06B -85.11M -83.25M -3.66B | -12.92M -14.77M -11.92M -11.01M -20.89M -1.41B -21.24M -142M -55.93M -694M -55.47M -54.26M -2.39B |
| Net Debt | 5.8M 6.63M 5.35M 4.94M 9.38M 632M 9.53M 63.92M 25.1M 312M 24.9M 24.36M 1.07B | 9M 10.29M 8.3M 7.67M 14.55M 981M 14.79M 99.19M 38.95M 483M 38.63M 37.79M 1.66B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
